Tetrasilver Tetroxide Product Page: A Fourth the source archive TSTO Capture (Sales-Page Variant)

This capture is the fourth Tetrasilver Tetroxide (TSTO) item ingested from the source archive, and it differs in kind from the three that precede it. Where the earlier captures were patent-and-sales dossiers built around Antelman's patent text and product literature, this one is a product/sales page — a commercial listing of TSTO formulations rather than a technical document. It presents TSTO as a multi-purpose antimicrobial agent sold in several product forms — SilverQuine Animal Wound Dressing, Tetrasil (also called Terrasil), and Genisil — and it reproduces an FDA warning letter concerning the marketing of Tetrasil and Genisil.

The page is short on structure and long on assertion. It contains no clinical trials, no independent replication, and no quantitative efficacy data. Its evidentiary weight rests on product marketing copy plus references to Antelman's patents. That pattern matches the three prior TSTO captures already in the wiki, and it is the reason this article is framed as a sales-page variant rather than a new technical finding.

What the source is

The capture corresponds to a source page in the tetrasilver/ directory (the TSTOProducts.html product listing). It is hosted by the source archive, the editor-led archive that collects inventor dossiers, patent references, and alternative-science material. The page's function is commercial: it enumerates TSTO-based products and their intended uses.

Because the page is promotional, the absence of test data is a property of the source itself, not a capture failure. The ingestion audit assigned this capture a low capture-problem probability (0.17), which is consistent with intact text whose content is simply marketing rather than measurement.

The subject: tetrasilver tetroxide

Tetrasilver Tetroxide (Ag₄O₄) (Ag₄O₄) is a mixed-valence silver oxide — a compound in which silver appears in more than one oxidation state within a single oxide lattice. That structural feature is the basis for the Mixed-Valence Silver Oxide concept and for the distinctive claims Antelman attaches to the material. The closely related Silver(I,III) Oxide (Silver(I,III) oxide) is a peripheral reference point in the TSTO literature.

The product page treats TSTO as a broad-spectrum antimicrobial agent, asserted to act against bacteria, viruses, and fungi. The applications named in the capture are topical skin and wound uses — minor cuts, lacerations, abrasions, burns, and skin irritations (SilverQuine), and viral, bacterial, and fungal skin conditions (Tetrasil/Genisil) — together with the FDA warning letter's account of the regulatory status of those claims.

Claimed mechanism

The mechanism asserted on the page is a micro-electrical charge and therapeutic-oxygen release said to kill pathogens on contact, together with a redox reaction and chelation of silver around viral surfaces. This framing is attributed in the source to the vendor and to Dr. Horowitz, and it is an assertion, not an independently established mechanism; the capture supplies no experimental demonstration of it.

It is important to keep two things separate here. The general antimicrobial action of silver — the Antimicrobial Silver and the Oligodynamic Effect — is a real and well-documented phenomenon: silver ions disrupt microbial cells at low concentrations. The TSTO-specific "electron jumping" mechanism and the product-specific efficacy claims are a different matter. The source conflates the genuine general phenomenon with unverified product claims, and the wiki preserves that distinction rather than collapsing it.

Applications claimed

• Topical wound and skin care — SilverQuine Animal Wound Dressing for minor cuts, lacerations, abrasions, first- and second-degree burns, and skin irritations.
• Topical antimicrobial skin ointments — Tetrasil/Terrasil and Genisil, marketed for viral, bacterial, and fungal skin conditions.
• Broad-spectrum antimicrobial action — bacteria, viruses, and fungi, as asserted in the marketing copy.

These are claims of intended use. The capture does not report dosing studies, kill-rate data, or comparative trials against established disinfectants.

Evidence and its limits

The evidence offered by the page is of two kinds: product marketing copy and references to Antelman's patents. Neither establishes efficacy. A patent documents a claim and a described embodiment; it is not proof that the claimed effect occurs as stated. The wiki treats this distinction explicitly under Patent as Evidence.

What is missing from this capture:

• No clinical trials or field trials.
• No independent replication by third parties.
• No quantitative efficacy data (no concentrations, contact times, or log-reduction figures).
• No characterization data for the material itself.

The Tetrasilver Tetroxide: The Electron-Jumping Claim, the Patent Set and the Bounded Evidence page holds the broader assessment across the TSTO dossier series; this capture reinforces that assessment rather than changing it.

Relationship to the other TSTO captures

This is the fourth TSTO item in the wiki. The three earlier captures are:

• Tetrasilver Tetroxide (TSTO): The source archive Sales-and-Patent Dossier — Tetrasilver Tetroxide (TSTO): The source archive Sales-and-Patent Dossier.
• Tetrasilver Tetroxide: The Electron-Jumping Claim, the Patent Set and the Negative Kinshasa Result — Tetrasilver Tetroxide: The source archive Sales-and-Patent Dossier.
• Tetrasilver Tetroxide: A Third source Capture (Variant Record) — Tetrasilver Tetroxide: A Third source Capture (Variant Record).

The open question flagged at ingestion is whether this fourth capture adds any product names, formulations, or patent numbers not already present in the three prior captures. If it does not, it is best understood as a near-duplicate variant — a different page from the same site presenting the same commercial claims — and should be recorded as such rather than expanded into new claims. The wiki's convention for these repeated captures is to keep each as its own source record while routing substantive content to the shared entity and concept pages.

Limitations and unresolved questions

• Promotional source. The page exists to sell products; its claims are not framed as findings.
• No independent corroboration. Nothing in the capture shows that anyone outside the vendor has tested the products.
• Mechanism unverified. The "electron jumping" model is Antelman's framing and is not demonstrated in the source.
• Variant status. Whether this capture is substantively distinct from the three prior TSTO captures remains open; the audit's low problem probability indicates the text is intact, not that the content is novel.

Related work

• Marvin S. Antelman — the chemist and inventor behind the TSTO claims and patents.
• Tetrasilver Tetroxide (Ag₄O₄) — the compound itself.
• Silver(I,III) Oxide — the related mixed-valence silver oxide.
• Antimicrobial Silver and the Oligodynamic Effect — the established general phenomenon.
• Mixed-Valence Silver Oxide — the structural basis of the material.
• Water Disinfection by Silver — the primary application claimed.
• Electron Jumping Compound / Molecular Battery Claim — the distinctive TSTO mechanism assertion.
• Patent as Evidence — why patent references do not establish efficacy.
• Tetrasilver Tetroxide: The Electron-Jumping Claim, the Patent Set and the Bounded Evidence — the cross-capture assessment.